Suppr超能文献

处方模式和遵守世界卫生组织建议治疗严重疟疾:加纳和乌干达公共卫生机构的改良队列事件监测研究。

Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda.

机构信息

The African Collaborating Centre for Pharmacovigilance & Surveillance, Accra, Ghana.

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.

出版信息

Malar J. 2019 Feb 8;18(1):36. doi: 10.1186/s12936-019-2670-9.

Abstract

BACKGROUND

Injectable artesunate (AS) is the World Health Organization (WHO) recommended medication for the treatment of severe malaria followed with an oral artemisinin-based combination therapy (ACT). There are few studies indicating how physicians prescribe injectable AS, injectable quinine (Q) or injectable artemether (AR) and ACT for severe malaria. This study was undertaken to evaluate prescription compliance to the WHO recommendation in 8 public health facilities in Ghana and Uganda. This was a modified cohort event monitoring study involving patients who were administered with injectable anti-malarial for treatment of presumed or confirmed severe malaria. Patients prescribed at least one dose of injectable artesunate, artemether or quinine qualified to enrol in the study. Patients were recruited at inpatient facilities and followed up in the hospital, by phone or at home. Following WHO recommendations, patients are to be prescribed 3 doses of injectable AS, Q or AR for at least 24 h followed with oral ACT. Compliance rate was estimated as the number of patient prescriptions that met the WHO recommendation for treatment of severe malaria divided by the total number of patients who completed the study by end of follow up. Log-binomial regression model was used to identify predictors for compliance. Based on the literature and limitations of available data from the patients' record, the diagnosis results, age, gender, weight, and country were considered as potential predictors of prescriber adherence to the WHO recommendations.

RESULTS

A total of 1191 patients completed the study, of which 93% were prescribed injectable AS, 3.1% (injectable AR or Q) with 32.5% prescribed follow-on oral ACT and 26% on concomitant antibiotics. 391 (32.8%) were in Ghana and 800 (67.2%) in Uganda. There were 582 (48.9%) women. The median age was 3.9 years (IQR = 2, 9) and median weight was 13 kg (IQR = 10, 20). Of the 1191 patients, 329 of the prescriptions complied with the WHO recommendation (compliance rate = 27.6%; 95% CI = [25.2, 30.2]). Diagnostic results (Adjusted prevalence ratio (aPR) = 4.56; 95% = [3.42, 6.08]; p < 0.0001) and weight (20 + kg vs < 10 kg: aPR = 0.65; 95% = [0.44, 0.96]; p = 0.015) were identified as factors independently associated with compliance.

CONCLUSION

Injectable AS is the most commonly prescribed medicine in the management of severe malaria in Ghana and Uganda. However, adherence to the WHO recommendation of at least 3 doses of injectable anti-malarial in 24 h followed by a full course of ACT is low, at less than 30%.

摘要

背景

注射用青蒿琥酯(AS)是世界卫生组织(WHO)推荐的治疗重症疟疾的药物,随后采用口服青蒿素类复方疗法(ACT)。目前,仅有少数研究表明医生如何开具注射用青蒿琥酯、奎宁(Q)或注射用青蒿素(AR)和 ACT 来治疗重症疟疾。本研究旨在评估加纳和乌干达 8 家公立卫生机构中,医生开具注射用 AS、注射用奎宁或注射用青蒿素以及 ACT 治疗重症疟疾的处方是否符合 WHO 推荐。这是一项改良的队列事件监测研究,涉及接受注射用抗疟药物治疗疑似或确诊重症疟疾的患者。至少接受一剂注射用青蒿琥酯、青蒿素或奎宁治疗的患者有资格入组研究。患者在住院病房入组,并在医院、通过电话或在家中接受随访。根据 WHO 建议,应为患者开具 3 剂注射用青蒿琥酯、奎宁或 AR,至少 24 小时,随后给予口服 ACT。根据 WHO 推荐治疗重症疟疾的患者处方数量,计算符合率,符合率为符合 WHO 推荐的重症疟疾治疗的患者处方数量除以完成随访的患者总数。采用对数二项式回归模型确定符合率的预测因素。根据文献和患者记录中诊断结果、年龄、性别、体重和国家的可用数据的局限性,将这些因素视为预测医生是否遵守 WHO 建议的潜在因素。

结果

共有 1191 例患者完成了研究,其中 93%的患者接受了注射用青蒿琥酯治疗,3.1%(注射用青蒿素或奎宁)的患者接受了后续的口服 ACT 治疗,26%的患者同时接受了抗生素治疗。391 例(32.8%)患者在加纳,800 例(67.2%)在乌干达。582 例(48.9%)为女性。中位年龄为 3.9 岁(IQR=2,9),中位体重为 13kg(IQR=10,20)。在 1191 例患者中,329 例处方符合 WHO 推荐(符合率=27.6%;95%CI=[25.2,30.2])。诊断结果(调整后的患病率比[aPR]=4.56;95%CI=[3.42,6.08];p<0.0001)和体重(20+kg 与<10kg:aPR=0.65;95%CI=[0.44,0.96];p=0.015)被确定为与符合率相关的独立因素。

结论

在加纳和乌干达,注射用青蒿琥酯是治疗重症疟疾最常用的药物。然而,在 24 小时内至少开具 3 剂注射用抗疟药物,随后完成全程 ACT 治疗的符合率低于 30%,即符合 WHO 推荐的治疗方案的比例较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/634c/6368732/e5701386761a/12936_2019_2670_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验